79 related articles for article (PubMed ID: 17762444)
1. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Garcia AA; Blessing JA; Vaccarello L; Roman LD;
Am J Clin Oncol; 2007 Aug; 30(4):428-31. PubMed ID: 17762444
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen CF; Levy T; Kudelka AP; Llerena E; Ende K; Freedman RS; Edwards CL; Hord M; Steger M; Kaplan AL; Kieback D; Fishman A; Kavanagh JJ
J Clin Oncol; 1997 Feb; 15(2):625-31. PubMed ID: 9053486
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Miller DS; Blessing JA; Bodurka DC; Bonebrake AJ; Schorge JO;
Gynecol Oncol; 2008 Jul; 110(1):65-70. PubMed ID: 18455781
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Look KY; Blessing JA; Gallup DG; Lentz SS
Am J Clin Oncol; 1996 Oct; 19(5):439-41. PubMed ID: 8823469
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
Alberts DS; Blessing JA; Landrum LM; Warshal DP; Martin LP; Rose SL; Bonebrake AJ; Ramondetta LM
Gynecol Oncol; 2012 Dec; 127(3):451-5. PubMed ID: 22986144
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Monk BJ; Sill MW; McMeekin DS; Cohn DE; Ramondetta LM; Boardman CH; Benda J; Cella D
J Clin Oncol; 2009 Oct; 27(28):4649-55. PubMed ID: 19720909
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.
Coleman RE; Harper PG; Gallagher C; Osborne R; Rankin EM; Silverstone AC; Slevin ML; Souhami RL; Tobias JS; Trask CW
Cancer Chemother Pharmacol; 1986; 18(3):280-3. PubMed ID: 3802384
[TBL] [Abstract][Full Text] [Related]
9. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.
Weiss GR; Green S; Hannigan EV; Boutselis JG; Surwit EA; Wallace DL; Alberts DS
Gynecol Oncol; 1990 Dec; 39(3):332-6. PubMed ID: 2258080
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G
J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.
Homesley HD; Meltzer NP; Nieves L; Vaccarello L; Lowendowski GS; Elbendary AA
Int J Clin Oncol; 2008 Feb; 13(1):62-5. PubMed ID: 18307021
[TBL] [Abstract][Full Text] [Related]
18. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
19. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Kudelka AP; Winn R; Edwards CL; Downey G; Greenberg H; Dakhil SR; Freedman RS; LoCoco S; Umbreit J; Delmore JE; Arbuck S; Loyer E; Gacrama P; Fueger R; Kavanagh JJ
Anticancer Drugs; 1997 Aug; 8(7):657-61. PubMed ID: 9311440
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
